RESOLUTE BIO
Resolute Bio is an emerging biotechnology company focused on empowering peptide and protein therapeutics.
RESOLUTE BIO
Social Links:
Industry:
Biotechnology Medical Therapeutics
Address:
Beverly, Massachusetts, United States
Country:
United States
Website Url:
http://www.resolutebio.com
Total Employee:
1+
Status:
Active
Contact:
(617) 834-5809
Email Addresses:
[email protected]
Official Site Inspections
http://www.resolutebio.com
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Resolute Bio"
About - Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). See details»
Rezolute, Inc. (RZLT)
Jun 5, 2025 Rezolute is a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases. See details»
Rezolute - Crunchbase Company Profile & Funding
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases. See details»
Rezolute (previously AntriaBio): Revenue, Worth, Valuation ...
Organization Rezolute (previously AntriaBio) rezolutebio.com Location Redwood City , California , United States Industry Biotech Share On: See details»
Rezolute, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
May 8, 2025 Explore Rezolute, Inc. with its drug pipeline, therapeutic area, technology platform, 6 clinical trials, 92 news, and 5 literature, Disease Domain:Endocrinology and ... See details»
Home - Rezolute, Inc.
Rezolute, Inc. is a biopharmaceutical company focused on developing transformative therapies for rare and metabolic diseases. See details»
Rezolute, Inc. Overview | SignalHire Company Profile
Rezolute, Inc. is a public company that has been in the industry for 14 years. The company currently specializes in the Biotechnology, Biotechnology, Pharmaceuticals areas. The position … See details»
Presentations :: Rezolute, Inc. (RZLT)
Contact Corporate Headquarters 275 Shoreline Drive Suite 500 Redwood City, CA 94065 +1 (650) 206-4507 [email protected] See details»
Resolute Bio 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Resolute Bio. Use the PitchBook Platform to explore the full profile. See details»
Contact Us - Rezolute, Inc.
We are a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs. See details»
Resolute Bio - Crunchbase Company Profile & Funding
Resolute Bio is an emerging biotechnology company focused on empowering peptide and protein therapeutics. See details»
Rezolute Announces Appointment of Rare Disease Commercial …
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative … See details»
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and ...
Feb 12, 2025 The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of … See details»
Join Us - Rezolute, Inc.
Benefits Rezolute partners with leading carriers, like Aetna, Blue Shield of California and Kaiser, to offer a broad range of medical plans, including high-deductible health plans, PPOs and HMOs. See details»
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe …
REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), announced today that the Company has appointed veteran … See details»
Pipeline - Rezolute, Inc.
Congenital Hyperinsulinism Congenital hyperinsulinism (cHI) is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. If left untreated, elevated … See details»
Rezolute Announces Appointment of Rare Disease Commercial
Mar 27, 2025 REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing … See details»
For Patients - Rezolute, Inc.
Connect With Us Whether you have been diagnosed with a condition that leads to frequent hypoglycemia due to elevated insulin levels or you are a representative of a patient advocacy … See details»
Rezolute Receives Breakthrough Therapy Designation from FDA …
May 5, 2025 The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of … See details»
Rezolute Receives Breakthrough Therapy Designation from FDA …
Jan 7, 2025 Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) … See details»